Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Gan & Lee Pharmaceuticals.

Clinicaltrial registered5 Nov 2026

Gan & Lee Pharmaceuticals.

5 Nov 2026: Trial registered · Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
5 Nov 2026
Title
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
Conditions
Healthy Participants
Phase
Phase 1
Study Type
Interventional
Status
Recruiting
Countries
China
Country
China
Reference
NCT07918898
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Gan & Lee Pharmaceuticals.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Gan & Lee Pharmaceuticals. in our registers.

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.